BNET Industries
Last Fiscal Year Sales:$1.2B
- Public
- US
Dow Jones Description
Founded in 1984, Sepracor was originally comprised of several diverse business units. In 1989, we embarked on a strategy of developing single isomers and active metabolites of many of the world's largest selling drugs, with the objective of developing our own proprietary pipeline of pharmaceutical products. Sepracor became a publicly traded corporation in 1991, and we subsequently divested our non-pharmaceutical business units into four different companies, retaining our core pharmaceutical business. Sepracor was built on the premise that chiral drugs could, in essence, be divided into two or more "parts" and that certain of these parts could be brought to the market as new medicines with the possibility for reduced side effects, greater potency or new indications. Sepracor was a pioneer in this area of drug development, identifying new, viable compounds. This strategy enabled Sepracor to establish itself initially by out-licensing the rights to a number of compounds to large, established pharmaceutical companies who developed and ultimately commercialized them. Some of these compounds have grown to become well-known brands in the pharmaceutical industry: ALLEGRA brand fexofenadine HCl, CLARINEX brand desloratadine and XYZAL /XUSALTM brand levocetirizine. ...
Number of Employees 2,400
Peer Companies
NAICS Code Pharmaceutical and Medicine Manufacturing: 3254
Recent Events
-
Sepracor CEO in line for $11M golden handshake
-
Data Missing On US Drug Labels
-
Sepracor deal closes, CEO in line for $11M
-
Standard & Poor's Announces Changes To U.S. Indices - Update
-
Levi & Korsinsky, LLP Announces Class Action Lawsuit Against Sepracor, Inc. -- SEPR
-
Sepracor investors try to derail $2.6B Dainippon buyout
-
Japanese Pharma on the Move Again With Lots of Acquisitions, Globalization
-
Dainippon Sumitomo to buy Sepracor
-
Dainippon Sumitomo To Acquire Sepracor For $2.6 Bln - Update
-
Dainippon to buy U.S. drug firm Sepracor for $2.6 billion
-
Lunesta Creative Travels to Lowe
-
Zacks Industry Rank Analysis Highlights: CVS Caremark, Life Technology, NuVasive, Inc., Sepracor and Gilead Sciences
-
Zacks Industry Rank Analysis Highlights: CVS Caremark, Life Technology, NuVasive, Inc.,...
-
Perrigo Confirms That its Partner Synthon Has Filed for Generic Version of XyzalR Solution and...
News & Analysis
Filter by
government and sepracor inc. - All News and Analysis
Sepracor Tested Sleeping Pill Lunesta on Kids
BNET
- 2009-07-06
The FDA stopped two clinical trials run by Sepracor studying sleeping pill Lunesta in children. The July 4 weekend is traditionally one of those times when companies drop bad news into the media in the hopes that America will be too busy eating and drinking to notice. This year was...
Sepracor Inc. Q3 2008 Earnings Conference Call Transcript
Seeking Alpha
- 2008-10-28
Question-and-Answer SessionThank you. And ladies and gentlemen, the floor is now open for questions. [Operator Instructions]. Our first question is from the line of Ian Sanderson with Cowen And Company. Please go ahead. Ian Sanderson - Cowen And Company Good morning. Thanks for taking the question. First of all...
Isiah Thomas Overdose Indicates Lunesta Has Chink in Armor
BNET
- 2008-10-26
Until now, Sepracor’s Lunesta sleeping pill has enjoyed one advantage over Sanofi-Aventis’s Ambien CR: a superior reputation for safety. The drug is approved by the FDA for long-term use, unlike many of its rivals. And it’s not a benzodiazepine. That reputation changed over the weekend as it...
Hot Stocks on the Move for Thursday! March 30, 2006.
- 2006-03-30
M2 PRESSWIRE-30 March 2006-Wall Street News Alert: Hot Stocks on the Move for Thursday! March 30, 2006C1994-2006 M2 COMMUNICATIONS LTD RDATE:30032006 Weston, FLA. - Wall Street News Alert's "stocks to watch" this morning are: ER Urgent Care Centers (OTC: ERUG), Rite ...
Marlborough, Mass., Drug Maker to Double Workforce, Launch Ad Campaign.
- 2004-03-01
By Ross Kerber, The Boston Globe Knight Ridder/Tribune Business News Mar. 1--Sepracor Inc. plans to roughly double its workforce to about 2,000 people and launch a major advertising campaign after receiving a conditional approval from the US Food and Drug Administration...
Massachusetts Drug Firm May Emerge Unscathed from Over-the-Counter Debate.
- 2001-05-16
By Naomi Aoki, The Boston Globe Knight Ridder/Tribune Business News May 16--In the campaign to make the nation's top-selling allergy drugs available without a prescription, Marlborough-based Sepracor Inc. may be the only drug company with a stake in the popular antihistamines to emerge unscathed....
The Law Firm of Shapiro Haber & Urmy Brings Suit With Expanded Class Period Against Sepracor, Inc. (NASDAQ: SEPR)
- 1970-01-01
A class action with an expanded class period of May 17, 1999 through March 6, 2002 (the "Class Period") has been filed in the United States District Court for the District of Massachusetts on behalf of purchasers of Sepracor, Inc. (NASDAQ: SEPR) common stock ("Sepracor" or "the Company"). The...
- 1
Industry Transcripts by Seeking Alpha
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
-
InterMune, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ITMN
Glass Door
Sepracor
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- More Tysabri Problems; Time for a Biogen-Idec Credibility Check 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes
- Fired Whistleblower Reps Make Similar Claim: Pfizer Said They Lacked "Integrity" 3 votes
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching 3 votes
